Nyt fra tidsskrifterne
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
47 ud af 47 tidsskrifter valgt, søgeord (influenza) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
209 emner vises.
Immunity, 12.08.2023
Tilføjet 12.08.2023
Publication date: Available online 11 August 2023 Source: Immunity Author(s): Erin E. West, Nicolas S. Merle, Marcin M. Kamiński, Gustavo Palacios, Dhaneshwar Kumar, Luopin Wang, Jack A. Bibby, Kirsten Overdahl, Alan K. Jarmusch, Simon Freeley, Duck-Yeon Lee, J. Will Thompson, Zu-Xi Yu, Naomi Taylor, Marc Sitbon, Douglas R. Green, Andrea Bohrer, Katrin D. Mayer-Barber, Behdad Afzali, Majid Kazemian
Læs mere Tjek på PubMedImmunity, 21.07.2023
Tilføjet 21.07.2023
Publication date: Available online 20 July 2023 Source: Immunity Author(s): Jenna M. Kastenschmidt, Suhas Sureshchandra, Aarti Jain, Jenny E. Hernandez-Davies, Rafael de Assis, Zachary W. Wagoner, Andrew M. Sorn, Mahina Tabassum Mitul, Aviv I. Benchorin, Elizabeth Levendosky, Gurpreet Ahuja, Qiu Zhong, Douglas Trask, Jacob Boeckmann, Rie Nakajima, Algimantas Jasinskas, Naresha Saligrama, D. Huw Davies, Lisa E. Wagar
Læs mere Tjek på PubMedInfectious Disease Modelling, 10.07.2023
Tilføjet 10.07.2023
Publication date: Available online 8 July 2023 Source: Infectious Disease Modelling Author(s): Yi Yin, Miao Lai, Sijia Zhou, Ziying Chen, Xin Jiang, Liping Wang, Zhongjie Li, Zhihang Peng
Læs mere Tjek på PubMedLaura Comber; Eamon O Murchu; Karen Jordan; Sarah Hawkshaw; Liam Marshall; Michelle O'Neill; Conor Teljeur; Máirín Ryan; AnnaSara Carnahan; Jaime Jesús Pérez Martín; Anna Hayman Robertson; Kari Johansen; Jorgen Jonge; Tyra Krause; Nathalie Nicolay; Hanna Nohynek; Ioanna Pavlopoulou; Richard Pebody; Pasi Penttinen; Marta Soler‐Soneira; Ole Wichmann; Patricia Harrington;
Reviews in Medical Virology, 10.05.2023
Tilføjet 10.05.2023
This review sought to assess the efficacy, effectiveness and safety of high‐dose inactivated influenza vaccines (HD‐IIV) for the prevention of laboratory‐confirmed influenza in individuals aged 18 years or older. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials (RCTs) and non‐randomised studies of interventions (NRSIs) were included. The search returned 28,846 records, of which 36 studies were included. HD‐IIV was shown to have higher relative vaccine efficacy in preventing influenza compared with standard‐dose influenza vaccines (SD‐IIV3) in older adults (Vaccine effectiveness (VE) = 24%, 95% CI 10–37, one RCT). One NRSI demonstrated significant effect for HD‐IIV3 against influenza B (VE = 89%, 95% CI 47–100), but not for influenza A(H3N2) (VE = 22%, 95% CI −82 to 66) when compared with no vaccination in older adults. HD‐IIV3 showed significant relative effect compared with SD‐IIV3 for influenza‐related hospitalisation (VE = 11.8%, 95% CI 6.4–17.0, two NRSIs), influenza‐ or pneumonia‐related hospitalisation (VE = 13.7%, 95% CI 9.5–17.7, three NRSIs), influenza‐related hospital encounters (VE = 13.1%, 95% CI 8.4–17.7, five NRSIs), and influenza‐related office visits (VE = 3.5%, 95% CI 1.5–5.5, two NRSIs). For safety, HD‐IIV were associated with significantly higher rates of local and systemic adverse events compared with SD‐IIV (combined local reactions, pain at injection site, swelling, induration, headache, chills and malaise). From limited data, compared with SD‐IIV, HD‐IIV were found to be more effective in the prevention of laboratory‐confirmed influenza, for a range of proxy outcome measures, and associated with more adverse events.
Læs mere Tjek på PubMedEamon O Murchu; Laura Comber; Karen Jordan; Sarah Hawkshaw; Liam Marshall; Michelle O’Neill; Máirín Ryan; Conor Teljeur; Annasara Carnahan; Jaime Jesús Pérez; Anna Hayman Robertson; Kari Johansen; Jorgen de Jonge; Tyra Krause; Nathalie Nicolay; Hanna Nohynek; Ioanna Pavlopoulou; Richard Pebody; Pasi Penttinen; Marta Soler‐Soneira; Ole Wichmann; Patricia Harrington;
Reviews in Medical Virology, 10.05.2023
Tilføjet 10.05.2023
The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of MF59 adjuvanted trivalent and quadrivalent influenza vaccines to prevent laboratory‐confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non‐randomised studies of interventions (NRSIs) were eligible for inclusion. The search returned 28,846 records, of which 48 studies on MF59 adjuvanted vaccines met our inclusion criteria. No efficacy trials were identified. In terms of vaccine effectiveness (VE), MF59 adjuvanted trivalent influenza vaccines were effective in preventing laboratory‐confirmed influenza in older adults (aged ≥65 years) compared with no vaccination (VE = 45%, 95% confidence interval (CI) 23%–61%, 5 NRSIs across 3 influenza seasons). By subtype, significant effect was found for influenza A(H1N1) (VE = 61%, 95% CI 44%–73%) and B (VE = 29%, 95% CI 5%–46%), but not for A(H3N2). In terms of relative VE, there was no significant difference comparing MF59 adjuvanted trivalent vaccines with either non‐adjuvanted trivalent or quadrivalent vaccines. Compared with traditional trivalent influenza vaccines, MF59 adjuvanted trivalent influenza vaccines were associated with a greater number of local adverse events (RR = 1.90, 95% CI 1.50–2.39) and systemic reactions (RR = 1.18, 95% CI 1.02–1.38). In conclusion, MF59 adjuvanted trivalent influenza vaccines were found to be more effective than ‘no vaccination’. Based on limited data, there was no significant difference comparing the effectiveness of MF59 adjuvanted vaccines with their non‐adjuvanted counterparts.
Læs mere Tjek på PubMedEamon O Murchu; Laura Comber; Karen Jordan; Sarah Hawkshaw; Liam Marshall; Michelle O’Neill; Máirín Ryan; Conor Teljeur; Annasara Carnahan; Jaime Jesús Pérez; Anna Hayman Robertson; Kari Johansen; Jorgen de Jonge; Tyra Krause; Nathalie Nicolay; Hanna Nohynek; Ioanna Pavlopoulou; Richard Pebody; Pasi Penttinen; Marta Soler‐Soneira; Ole Wichmann; Patricia Harrington;
Reviews in Medical Virology, 10.05.2023
Tilføjet 10.05.2023
The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of recombinant haemagglutinin (HA) seasonal influenza vaccines to prevent laboratory‐confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non‐randomised studies of interventions were eligible for inclusion. The search returned 28,846 records, of which 10 studies on recombinant HA influenza vaccine met our inclusion criteria. One study found that the quadrivalent recombinant HA influenza vaccine had higher relative vaccine efficacy (rVE) in preventing laboratory‐confirmed influenza during the 2014–15 season compared with traditional quadrivalent vaccination in adults aged ≥50 years (rVE = 30%, 95% CI 10%–47%, moderate‐certainty evidence). In a subgroup analysis, higher rVE was reported for influenza A (rVE = 36%, 95% CI 14% to 53%), but not for B (non‐significant). Another study reported higher efficacy for the trivalent recombinant HA vaccine compared with placebo (VE = 45%, 95% CI 19–63, 1 RCT, low‐certainty evidence) in adults aged 18–55 years. With the exception of a higher rate of chills (RR = 1.33, 95% CI 1.03–1.72), the safety profile of recombinant HA vaccines was comparable to that of traditional influenza vaccines. The evidence base for the efficacy and effectiveness of recombinant HA influenza vaccines is limited at present, although one study found that the quadrivalent recombinant HA influenza vaccine had higher rVE compared with traditional quadrivalent vaccination in adults aged ≥50 years.
Læs mere Tjek på PubMedKaren Jordan; Eamon O. Murchu; Laura Comber; Sarah Hawkshaw; Liam Marshall; Michelle O’Neill; Conor Teljeur; Patricia Harrington; Annasara Carnahan; Jaime Jesús Pérez‐Martín; Anna Hayman Robertson; Kari Johansen; Jorgen de Jonge; Tyra Krause; Nathalie Nicolay; Hanna Nohynek; Ioanna Pavlopoulou; Richard Pebody; Pasi Penttinen; Marta Soler‐Soneira; Ole Wichmann; Máirín Ryan;
Reviews in Medical Virology, 10.05.2023
Tilføjet 10.05.2023
The most effective means of preventing seasonal influenza is through strain‐specific vaccination. In this study, we investigated the efficacy, effectiveness and safety of cell‐based trivalent and quadrivalent influenza vaccines. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials (RCTs) and non‐randomised studies of interventions (NRSIs) were eligible for inclusion. Two reviewers independently screened, extracted data and assessed the risk of bias of included studies. Certainty of evidence for key outcomes was assessed using the GRADE methodology. The search returned 28,846 records, of which 868 full‐text articles were assessed for relevance. Of these, 19 studies met the inclusion criteria. No relative efficacy data were identified for the direct comparison of cell‐based vaccines compared with traditional vaccines (egg‐based). Efficacy data were available comparing cell‐based trivalent influenza vaccines with placebo in adults (aged 18–49 years). Overall vaccine efficacy was 70% against any influenza subtype (95% CI 61%–77%, two RCTS), 82% against influenza A(H1N1) (95% CI 71%–89%, 2 RCTs), 72% against influenza A(H3N2) (95% CI 39%–87%, 2 RCTs) and 52% against influenza B (95% CI 30%–68%, 2 RCTs). Limited and heterogeneous data were presented for effectiveness when compared with no vaccination. One NRSI compared cell‐based trivalent and quadrivalent vaccination with traditional trivalent and quadrivalent vaccination, finding a small but significant difference in favour of cell‐based vaccines for influenza‐related hospitalisation, hospital encounters and physician office visits. The safety profile of cell‐based trivalent vaccines was comparable to traditional trivalent influenza vaccines. Compared with placebo, cell‐based trivalent influenza vaccines have demonstrated greater efficacy in adults aged 18–49 years. Overall cell‐based vaccines are well‐tolerated in adults, however, evidence regarding the effectiveness of these vaccines compared with traditional seasonal influenza vaccines is limited.
Læs mere Tjek på PubMedInfectious Disease Modelling, 7.05.2023
Tilføjet 7.05.2023
Publication date: Available online 6 May 2023 Source: Infectious Disease Modelling Author(s): Georges Bucyibaruta, C.B. Dean, Mahmoud Torabi
Læs mere Tjek på PubMedSourabh Soni; Yohannes A. Mebratu;
Reviews in Medical Virology, 24.04.2023
Tilføjet 24.04.2023
The COVID‐19 pandemic caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) has led to a global health emergency. There are many similarities between SARS‐CoV‐2 and influenza A virus (IAV); both are single‐stranded RNA viruses infecting airway epithelial cells and have similar modes of replication and transmission. Like IAVs, SARS‐CoV‐2 infections poses serious challenges due to the lack of effective therapeutic interventions, frequent appearances of new strains of the virus, and development of drug resistance. New approaches to control these infectious agents may stem from cellular factors or pathways that directly or indirectly interact with viral proteins to enhance or inhibit virus replication. One of the emerging concepts is that host cellular factors and pathways are required for maintaining viral genome integrity, which is essential for viral replication. Although IAVs have been studied for several years and many cellular proteins involved in their replication and pathogenesis have been identified, very little is known about how SARS‐CoV‐2 hijacks host cellular proteins to promote their replication. IAV induces apoptotic cell death, mediated by the B‐cell lymphoma‐2 (Bcl‐2) family proteins in infected epithelia, and the pro‐apoptotic members of this family promotes viral replication by activating host cell proteases. This review compares the life cycle and mode of replication of IAV and SARS‐CoV‐2 and examines the potential roles of host cellular proteins, belonging to the Bcl‐2 family, in SARS‐CoV‐2 replication to provide future research directions.
Læs mere Tjek på PubMed